Media headlines about Soligenix (NASDAQ:SNGX) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Soligenix earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.2218150525621 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Soligenix (NASDAQ:SNGX) opened at 2.32 on Tuesday. The firm’s market capitalization is $13.16 million. Soligenix has a one year low of $2.08 and a one year high of $14.40. The stock has a 50 day moving average of $2.26 and a 200-day moving average of $2.45.

Soligenix (NASDAQ:SNGX) last announced its earnings results on Friday, August 11th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.09. The firm had revenue of $1 million during the quarter, compared to analysts’ expectations of $1.43 million. Soligenix had a negative net margin of 41.74% and a negative return on equity of 102.83%. On average, equities analysts anticipate that Soligenix will post ($1.26) earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the stock. HC Wainwright set a $11.00 price objective on shares of Soligenix and gave the company a “buy” rating in a report on Monday. Maxim Group raised their price objective on shares of Soligenix from $4.00 to $5.00 and gave the company a “buy” rating in a report on Monday.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.